Granted (in shares) Awards granted in period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Deferred revenue Increase (Decrease) in Contract with Customer, Liability Document Type Document Type Aggregate Intrinsic Value, Outstanding, Ending Balance Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Fair Value Disclosures [Abstract] Other income Other Nonoperating Income (Expense) Marketable securities Investments Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Amortization of premiums and discounts on marketable securities Accretion (Amortization) of Discounts and Premiums, Investments Potential commercial milestone payments under agreement PotentialCommercialMilestonePaymentsUnderAgreement Cost of product sales Cost of Goods and Services Sold Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Securities Fair Value Debt Securities, Available-for-sale Marketable Securities Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Total costs and expenses Costs and Expenses Equity Components [Axis] Equity Components [Axis] Exercised (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Share-based Payment Arrangement [Abstract] Minimum Minimum [Member] Lease liabilities Operating Lease, Liability, Current Total unrecognized compensation cost Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Lease liabilities Increase (decrease) in lease liabilities Increase (decrease) in lease liabilities Potential proceeds from royalties (percent) ProceedsfromRoyaltiesPercent Range [Domain] Statistical Measurement [Domain] Liabilities and stockholders' equity Liabilities and Equity [Abstract] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Forfeited or expired (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Valuation Assumptions Using the Black-Scholes Option-Pricing Model Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] NIAID NationalInstituteOfAllergyAndInfectiousDiseasesMember Entity Interactive Data Current Entity Interactive Data Current Weighted- Average Exercise Price, Exercised (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Revenues: Revenues [Abstract] Security Exchange Name Security Exchange Name Fair Value of Financial Instruments Fair Value Disclosures [Text Block] Cash flows from operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] Stockholders' Equity Stockholders' Equity Note Disclosure [Text Block] Non-refundable upfront payment, net of tax withholding Nonrefundable Upfront Fees, Net Of Tax Withholding Nonrefundable Upfront Fees, Net Of Tax Withholding Loss from operations Operating Income (Loss) Total current liabilities Liabilities, Current Additional paid-in capital Additional Paid in Capital, Common Stock Entity Registrant Name Entity Registrant Name Statement of Stockholders' Equity [Abstract] Assets: Assets, Fair Value Disclosure [Abstract] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Beginning Balance (in dollars per share) Ending Balance (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Revenues, tax withholding Revenues, Tax Withholding Revenues, Tax Withholding Assets Assets [Abstract] Accounting Policies [Abstract] Weighted- Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Incyte MGA012 Supply Agreement Incyte MGA012 Supply Agreement [Member] Incyte MGA012 Supply Agreement Incyte MGA012 Agreement IncyteMGA012AgreementMember Proceeds from additional development funding options under agreement ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement Entity Address, State or Province Entity Address, State or Province Accounts payable Accounts Payable, Current Research and Development Research and Development Expense [Member] Available-for-sale Marketable Securities Available-for-sale Securities [Table Text Block] Accumulated deficit Retained Earnings (Accumulated Deficit) Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Cost of Product Sales Cost of Goods and Service [Policy Text Block] Stock Option and Restricted Stock Unit Activity ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivity [Table Text Block] Accumulated other comprehensive income (loss) AOCI, Debt Securities, Available-for-sale, Adjustment, after Tax Options outstanding (in shares) Shares, Outstanding, Beginning Balance (in shares) Shares, Outstanding, Ending Balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Gross Unrealized Losses Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax Unrecognized compensation expense related to non-vested stock-options, net of related forfeiture estimates Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Sale of Stock [Axis] Sale of Stock [Axis] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Purchase price of common stock percent of the fair market value Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-sale [Line Items] Non-refundable upfront payment NonRefundableUpfrontFees Document Transition Report Document Transition Report Shares, Exercisable (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Other comprehensive income (loss): Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Other non current liabilities Other Liabilities, Noncurrent Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Fair value of shares vested Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value Share-based compensation APIC, Share-based Payment Arrangement, Increase for Cost Recognition Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Document Quarterly Report Document Quarterly Report Inventory Inventory, Net Shares, Forfeited or expired (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Fair Value, Measurement Frequency [Domain] Measurement Frequency [Domain] Asset Class [Domain] Asset Class [Domain] General and Administrative General and Administrative Expense [Member] Equity [Abstract] Total assets measured at fair value Assets, Fair Value Disclosure Proceeds from stock option exercises and ESPP purchases ProceedsfromStockOptionsExercisedAndESPPPurchases Janssen Biotech Inc Janssen Biotech Inc [Member] Janssen Biotech Inc Deferred revenue Deferred revenue, current Contract with Customer, Liability, Current Incyte MGA012 Agreement - Clinical activities IncyteMGA012AgreementClinicalActivitiesMember Maximum amount available for issuance Common Stock, Maximum Amount Available For Issuance Common Stock, Maximum Amount Available For Issuance Weighted- Average Exercise Price, Granted (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Statement [Line Items] Statement [Line Items] Shares, Vested and expected to vest (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Diluted weighted average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Diluted Incyte MGA012 Clinical Services Incyte MGA012 Clinical Services [Member] Incyte MGA012 Clinical Services Financial Assets Measured at Fair Value on a Recurring Basis Fair Value Measurements, Recurring and Nonrecurring [Table Text Block] Basic net loss per common share (in usd per share) Earnings Per Share, Basic Unrealized gain (loss) on investments Unrealized Gain (Loss) on Investments Expected term Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Entity File Number Entity File Number License And Collaboration Agreements [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Forfeited or expired (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Statement [Table] Statement [Table] Range [Axis] Statistical Measurement [Axis] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Stock-based compensation expense Share-based Payment Arrangement, Expense Potential development and regulatory milestone payments under agreement PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement Retirement Of Treasury Stock Retirement Of Treasury Stock Retirement Of Treasury Stock Counterparty Name [Axis] Counterparty Name [Axis] Common stock, $0.01 par value -- 125,000,000 shares authorized, 60,133,447 and 56,244,771 shares outstanding at June 30, 2021 and December 31, 2020, respectively Common Stock, Value, Issued At the Market Offering At The Market Offering [Member] At The Market Offering Document Fiscal Year Focus Document Fiscal Year Focus Entity Small Business Entity Small Business Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Aggregate Intrinsic Value, Exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Premium received on stock purchase PremiumReceivedOnStockPurchase PremiumReceivedOnStockPurchase Nonrefundable payment tax withholding Nonrefundable Payment Tax Withholding Nonrefundable Payment Tax Withholding Number of shares sold (in shares) Sale of Stock, Number of Shares Issued in Transaction Entity Current Reporting Status Entity Current Reporting Status Sales of stock purchase price (in dollars per share) Sale of Stock, Price Per Share Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Weighted- Average Remaining Contractual Term, Exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Base period amount FundedValueOfBasePeriod Proceeds from issuance of common stock, net of offering costs Proceeds from Issuance of Common Stock Total inventory Inventory, Work in Process and Raw Materials Proceeds from sale and maturities of marketable securities Proceeds from Sale and Maturity of Debt Securities, Available-for-sale Amendment Flag Amendment Flag Purchases of marketable securities Payments to Acquire Debt Securities, Available-for-sale Granted (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Share-based compensation, number of shares authorized (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Inventory Disclosure [Abstract] Cash flows from investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Estimated variable consideration Revenue, Information Used To Assess Variable Consideration, Amount Revenue, Information Used To Assess Variable Consideration, Amount Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Revenue from collaborative and other agreements RevenueFromCollaborativeAgreementsMember Zai Lab Clinical Supply Agreements Zai Lab Clinical Supply Agreements [Member] Zai Lab Clinical Supply Agreements Accounts payable Increase (Decrease) in Accounts Payable and Other Operating Liabilities Entity Central Index Key Entity Central Index Key Measurement Frequency [Axis] Measurement Frequency [Axis] Zai Lab Agreement, TRIDENT molecule Zai Labs Collaboration And License Agreement, TRIDENT molecule [Member] Zai Labs Collaboration And License Agreement, TRIDENT molecule Accounts receivable Increase (Decrease) in Accounts Receivable Financial Instruments [Domain] Financial Instruments [Domain] Total stockholders' equity Stockholders' Equity Attributable to Parent Total liabilities and stockholders' equity Liabilities and Equity Raw materials Inventory, Raw Materials, Gross Property, equipment and software included in accounts payable or accruals Capital Expenditures Incurred but Not yet Paid Entity Address, City or Town Entity Address, City or Town Common stock purchased (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Restricted Stock Units Restricted Stock Units (RSUs) [Member] Collaboration and Other Agreements Collaboration And Other Agreements Disclosure [Text Block] Selling, general and administrative General and Administrative Expense Financial Instrument [Axis] Financial Instrument [Axis] Amortized Cost Debt Securities, Available-for-sale, Amortized Cost Gross Unrealized Gains Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax Statement of Cash Flows [Abstract] Development and regulatory milestones recognized Development And Regulatory Milestone Payments Under Agreement, Recognized Development And Regulatory Milestone Payments Under Agreement, Recognized Product revenue, net Product [Member] Potential milestone payments and royalties on product sales Potential Milestone Payments and Royalties On Product Sales Potential Milestone Payments and Royalties On Product Sales Schedule of RSU Activity Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Equity Component [Domain] Equity Component [Domain] Income Statement Location [Axis] Income Statement Location [Axis] Unrealized gain (loss) on investments OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Zai Lab Agreement, Margetuximab Zai Labs Collaboration And License Agreement, Margetuximab [Member] Zai Labs Collaboration And License Agreement, Margetuximab Income Statement Location [Domain] Income Statement Location [Domain] Cash flows from financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Property, equipment and software, net Property, Plant and Equipment, Net Entity Tax Identification Number Entity Tax Identification Number 2018 Zai Lab Agreement 2018 Zai Lab Collaboration And License Agreement [Member] 2018 Zai Lab Collaboration And License Agreement 2016 Employee Stock Purchase Plan TwoThousandSixteenEmployeeStockPurchasePlanMember Stock-Based Compensation Share-based Payment Arrangement [Text Block] Net loss Net loss Net loss Net Income (Loss) Attributable to Parent Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Other assets Other Assets, Noncurrent Plan Name [Axis] Plan Name [Axis] Inventory Inventory Disclosure [Text Block] Work in process Inventory, Work in Process, Gross Debt Securities, Trading, and Equity Securities, FV-NI [Table] Debt Securities, Trading, and Equity Securities, FV-NI [Table] Issuance of common stock, net of offering costs Stock Issued During Period, Value, New Issues Cash and cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Nature of Operations Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Total assets Assets Total current assets Assets, Current Current Fiscal Year End Date Current Fiscal Year End Date Beginning Balance (in shares) Ending Balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Incyte Corporation IncyteCorporationMember Title of 12(b) Security Title of 12(b) Security Revenues, net of tax withholding Revenues, Net Of Tax Withholding Revenues, Net Of Tax Withholding Weighted-average grant-date fair value of options granted (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Revenues From Grants RevenuesFromGrantsMember Investments, Debt and Equity Securities [Abstract] Stockholders' equity: Stockholders' Equity Attributable to Parent [Abstract] Shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Potential annual increase in shares reserved for future issuance as percentage of outstanding share PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan Document Fiscal Period Focus Document Fiscal Period Focus Proceeds of stock sale Sale of Stock, Consideration Received on Transaction Depreciation and amortization expense Depreciation, Depletion and Amortization Payroll deduction discount EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent Product and Service [Axis] Product and Service [Axis] Total liabilities Liabilities Deferred revenue, net of current portion Contract with Customer, Liability, Noncurrent Janssen Collaboration and License Agreement Janssen Collaboration And License Agreement [Member] Janssen Collaboration And License Agreement Stock plan related activity (in shares) Shares, Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures Supplemental Cash Flow Information [Abstract] Supplemental Cash Flow Information [Abstract] Unrecognized compensation expense recognition period Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Expected volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Weighted- Average Remaining Contractual Term, Vested and expected to vest Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Entity Filer Category Entity Filer Category Stock-Based Compensation Expense Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Common Stock Common Stock [Member] Product and Service [Domain] Product and Service [Domain] Commitments and Contingencies Disclosure [Abstract] Quoted Prices in Active Markets for Identical Assets (Level 1) Fair Value, Inputs, Level 1 [Member] Inventory Increase (Decrease) in Inventories Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Shares Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Additional development funding options under agreement AdditionalDevelopmentFundingOptionsUnderAgreement U.S. Treasury securities US Treasury Securities [Member] Issuance of common stock, net of offering costs (in shares) Stock Issued During Period, Shares, New Issues I-Mab I-Mab Biopharma [Member] I-Mab Biopharma Commercialization of molecules NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement Additional Paid-In Capital Additional Paid-in Capital [Member] Money market funds Money Market Funds [Member] Class of Stock [Line Items] Class of Stock [Line Items] Accrued expenses and other current liabilities Increase (Decrease) in Accrued Liabilities Aggregate Intrinsic Value, Vested and expected to vest Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Asset Class [Axis] Asset Class [Axis] Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Beginning balance (in shares) Ending balance (in shares) Shares, Issued Shares, Exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Net change in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Basic weighted average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Costs and expenses: Costs and Expenses [Abstract] Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Research and development Research and Development Expense Weighted- Average Exercise Price, Forfeited or expired (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Weighted-average exercise price of stock options outstanding (in dollars per share) Weighted- Average Exercise Price, Outstanding, Beginning Balance (in dollars per share) Weighted- Average Exercise Price, Outstanding, Ending Balance (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Sale of Stock [Domain] Sale of Stock [Domain] I-Mab Biopharma Collaboration and License Agreement I-Mab Biopharma Collaboration And License Agreement [Member] I-Mab Biopharma Collaboration And License Agreement Common stock, shares authorized (in shares) Common Stock, Shares Authorized Cash received for options exercised Proceeds from Stock Options Exercised Plan Name [Domain] Plan Name [Domain] Other non current liabilities Increase (Decrease) in Other Current Liabilities Product Revenue, Reserves for Variable Consideration, Customer Discounts and Services Fees, Product Returns, Provider Chargebacks and Discounts, and Government Rebates Revenue [Policy Text Block] Beginning balance Ending balance Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Revenues Revenues Collaboration And Other Agreements [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Inventory Inventory, Policy [Policy Text Block] Revenue From Performance of the Research and Development Activities Revenue From Performance Of The Research And Development Activities [Member] Revenue From Performance Of The Research And Development Activities Income Statement [Abstract] Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Lease liabilities, net of current portion Operating Lease, Liability, Noncurrent Accrued expenses and other current liabilities Accrued Liabilities, Current Collaborative agreement transaction price CollaborativeAgreementTransactionPrice Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Diluted net loss per common share (in usd per share) Earnings Per Share, Diluted Local Phone Number Local Phone Number Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Intrinsic value of options exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Zai Labs Zai Lab [Member] Zai Lab Current assets: Assets, Current [Abstract] Accumulated Other Comprehensive Income (Loss) AOCI Including Portion Attributable to Noncontrolling Interest [Member] Entity Address, Address Line One Entity Address, Address Line One Deferred revenue Contract with Customer, Liability Other assets Increase (Decrease) in Other Operating Assets Entity Emerging Growth Company Entity Emerging Growth Company Revenues From License Agreements RevenuesFromLicenseAgreementsMember Revenue from government agreements RevenueFromGovernmentAgreementsMember Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Expected dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Government-sponsored enterprises US Government-sponsored Enterprises Debt Securities [Member] 2003 Stock Incentive Plan A2003StockIncentivePlanMember Award Type [Axis] Award Type [Axis] Weighted-Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Number of performance obligations Number Of Performance Obligations Exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised Opt-in fee Opt-in Fee Opt-in Fee Counterparty Name [Domain] Counterparty Name [Domain] Purchases of property, equipment and software Payments to Acquire Property, Plant, and Equipment City Area Code City Area Code Variable consideration recognized Clinical trial activities selling price amount Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount Maximum Maximum [Member] Document Period End Date Document Period End Date Accumulated Deficit Retained Earnings [Member] Allowance for credit loss related to available-for-sale debt securities Debt Securities, Available-for-sale, Allowance for Credit Loss Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Weighted- Average Remaining Contractual Term, Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Award Type [Domain] Award Type [Domain] Total potential value TotalPotentialValueUnderAgreement 2021 Zai Lab Agreements 2021 Zai Lab Agreements [Member] 2021 Zai Lab Agreements Stock plan related activity Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture Corporate debt securities Corporate Debt Securities [Member] Trading Symbol Trading Symbol Weighted- Average Exercise Price, Exercisable (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Maximum amount available for issuance, increase Common Stock, Maximum Amount Available For Issuance, Increase Common Stock, Maximum Amount Available For Issuance, Increase Potential annual increase in shares reserved for future issuance (in shares) CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance Schedule of Inventory Schedule of Inventory, Current [Table Text Block] Stock-based compensation Share-based Payment Arrangement, Noncash Expense Stock Incentive Plan 2013 StockIncentivePlan2013Member Cover [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Current liabilities: Liabilities, Current [Abstract] Collaboration and License Agreements [Abstract] Collaboration and License Agreements [Abstract] Entity Shell Company Entity Shell Company Fair Value Measurements, Recurring Basis Fair Value, Recurring [Member] Weighted- Average Exercise Price, Vested and expected to vest (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Statement of Financial Position [Abstract]